MAPT and Alzheimer disease: With this multicentre study, we validated the utility of the novel N-224 tau assay, previously shown as AD specific [3], in two independent clinical cohorts, and evaluated its potential to distinguish clinically diagnosed AD patients from controls, SCD, MCI and non-AD patients.